Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
CAPRCapricor Therapeutics(CAPR) Zacks Investment Research·2024-05-14 06:15

Capricor Therapeutics (CAPR) came out with a quarterly loss of 0.31pershareversustheZacksConsensusEstimateofalossof0.31 per share versus the Zacks Consensus Estimate of a loss of 0.11. This compares to loss of 0.31pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof−181.820.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -181.82%. A quarter ago, it was expected that this biotechnology company would post a loss of 0.23 per share when it actually produced a loss of $0.02, delivering a surprise of 91.30%. Over the last four quarters, ...